WuXi AppTec Co., Ltd. (WUXAY)

OTCMKTS · Delayed Price · Currency is USD
14.24
+1.61 (12.77%)
Jul 29, 2025, 3:45 PM EDT
12.77%
Market Cap39.32B
Revenue (ttm)5.79B
Net Income (ttm)1.92B
Shares Outn/a
EPS (ttm)0.56
PE Ratio20.45
Forward PE22.00
Dividend0.14 (1.12%)
Ex-Dividend DateMay 19, 2025
Volume100
Average Volume4,972
Open13.81
Previous Close12.63
Day's Range13.81 - 14.95
52-Week Range3.56 - 14.95
Beta0.76
RSI86.87
Earnings DateJul 27, 2025

About WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecula... [Read more]

Sector Healthcare
Founded 2000
Employees 39,414
Stock Exchange OTCMKTS
Ticker Symbol WUXAY
Full Company Profile

Financial Performance

In 2024, WuXi AppTec's revenue was 37.92 billion, a decrease of -1.97% compared to the previous year's 38.68 billion. Earnings were 9.45 billion, a decrease of -1.63%.

Financial numbers in CNY Financial Statements

News

WuXi AppTec Co., Ltd. (WUXIF) Q2 2025 Earnings Call Transcript

WuXi AppTec Co., Ltd. (OTCPK:WUXIF) Q2 2025 Earnings Conference Call July 28, 2025 9:00 PM ET Company Participants Ming Shi - Senior VP & CFO Minzhang Chen - Co-CEO & Executive Director Qing Yang - Co...

20 hours ago - Seeking Alpha

WuXi AppTec Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations[1] Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY

Total Revenue Reached RMB11.14 Billion in the Second Quarter, Up 20.4% Year-over-Year; among which Revenue from Continuing Operations Reached RMB11.05 Billion, Up 24.9% Year-over-Year Total Revenue Re...

1 day ago - PRNewsWire

WuXi AppTec Issues Positive Profit Alert for the First Half of 2025

SHANGHAI , July 10, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH/2359.HK), a leading global pharmaceutical and life sciences technology platform company offering integrated, end-t...

19 days ago - PRNewsWire

WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities

SHANGHAI , July 7, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies i...

21 days ago - PRNewsWire

WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity

SHANGHAI , June 26, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...

4 weeks ago - PRNewsWire

WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets

SHANGHAI , June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...

6 weeks ago - PRNewsWire

Focus: China pharma projects disrupted by Sino-US tensions

Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of th...

6 weeks ago - Reuters

WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors

SHANGHAI , June 16, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...

6 weeks ago - PRNewsWire

WuXi AppTec Co., (WUXIF) Ltd. Q1 2025 Earnings Call Transcript

WuXi AppTec Co.

3 months ago - Seeking Alpha

WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY

Total Revenue Reached RMB9.65 Billion, Up 21.0% Year-over-Year; among which Revenue from Continuing Operations Reached RMB9.39 Billion, Up 23.1% Year-over-Year Net Profit Attributable to the Owners of...

3 months ago - PRNewsWire

WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections

SHANGHAI , March 31, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences in...

4 months ago - PRNewsWire

WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs

Fourth-Quarter Revenue Reached RMB11,539 Million, Up 6.9% Year-over-Year 2024 Revenue Reached RMB39,241 Million, Up 5.2% Year-over-Year (Excluding COVID-19 Commercial Project of 2023) Full-Year Net Pr...

4 months ago - PRNewsWire

WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)

SHANGHAI , Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ind...

7 months ago - PRNewsWire

WuXi AppTec's Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year

SHANGHAI , Dec. 30, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...

7 months ago - PRNewsWire

WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating

COUVET, Switzerland , Nov. 14, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life s...

9 months ago - PRNewsWire

WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

SHANGHAI , Oct. 29, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...

9 months ago - PRNewsWire

Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY

Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-...

9 months ago - PRNewsWire

WuXi AppTec to raise $500 mln in convertible bond sale as US restrictions loom

China's WuXi AppTec , will raise $500 million in a convertible bond sale, according to a regulatory filing on Tuesday, a month after the U.S. passed rules to restrict business with the firm on nationa...

10 months ago - Reuters

US bill to restrict business with China's WuXi AppTec, BGI passes House

The U.S. House of Representatives on Monday passed a bill that aims to restrict business with China's WuXi AppTec , BGI and several other biotech companies on national security grounds.

11 months ago - Reuters

US House committee to vote on bill to restrict BGI, WuXi AppTec

U.S. legislation that would restrict business with China's BGI, WuXi AppTec and certain other biotech companies on national security grounds will be voted on by a committee in the House of Representat...

1 year ago - Reuters

U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties

A new version of a bill that would restrict U.S. business with China's WuXi AppTec, BGI and other biotechnology companies of concern would allow companies until 2032 to end work with the Chinese firms...

1 year ago - Reuters

WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations

Revenue Reached RMB7,982 Million; Excluding COVID-19 Commercial Projects, Down 1.8% Net Profit Attributable to the Owners of the Company Reached RMB1,942 Million; Diluted Earnings per Share (EPS) Reac...

1 year ago - PRNewsWire

Exclusive: China's WuXi AppTec shared US client's data with Beijing, US intelligence officials told senators

U.S. intelligence officials in late February told senators working on a biotech security bill that Chinese pharmaceutical firm WuXi AppTec had transferred U.S. intellectual property to Beijing without...

1 year ago - Reuters

China's WuXi AppTec In Crosshairs of US Draft Biosecurity Bill

A draft US law is casting a cloud over some Chinese pharma firms, as it aims to block certain foreign biotech companies from accessing US federal contracts on national security grounds. Bloomberg's Mi...

1 year ago - Bloomberg Markets and Finance

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time

Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6% Net Profit Attributable to the Owners of the Company [1] Increased 9.0% to RMB9,607 Million; Dilut...

1 year ago - PRNewsWire